Vertex Pharmaceuticals authorizes $4.0B share repurchase program

VERTEX PHARMACEUTICALS INC / MA

Board authorized new $4.0B stock repurchase program (2025 Repurchase Program) with no expiration date.
Combined with ~$775M remaining under 2023 program, total authorization rises to ~$4.775B.
Repurchases may be made on open market or private transactions, including under Rule 10b5-1 plans.
Company can discontinue program at any time; repurchases subject to market conditions and other opportunities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.